Standigm - About the company
Standigm is a series C company based in Seoul (South Korea), founded in 2015 by Jinhan Kim and So Jeong Yun. It operates as an AI-based platform for drug discovery and development. Standigm has raised $69.6M in funding from investors like LB Investment, SK Chemicals and Atinum Investment. The company has 147 active competitors, including 64 funded and 10 that have exited. Its top competitors include companies like Recursion Pharmaceuticals, XtalPi and Schrodinger.
Company Details
AI-based platform for drug discovery and development. The company has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Its products include DarkMolFactory for molecular design, Standigm ASK for target discovery, Standigm BEST for lead design, and Standigm Insight for drug repurposing.
- Website
- standigm.com
- Social
- Email ID
- *****@standigm.com
- Phone Number
- +82 **********
- Registered Address
- SUITE 465, BUILDING 4, NORTH LONDON BUSINESS PARK,OAKLEIGH ROAD SOUTH,LONDON,UNITED KINGDOM,N11 1GN
Key Metrics
Founded Year
2015
Location
Seoul, South Korea
Stage
Series C
Total Funding
$69.6M in 5 rounds
Latest Funding Round
Investors
Ranked
31st among 147 active competitors
Employee Count
25 as on Mar 31, 2026
Similar Companies
Legal entities associated with Standigm
Standigm is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
STANDIGM UK CO., LTD CIN: 13631062 , United Kingdom, Active | Sep 19, 2021 | - | 2 (As on Sep 30, 2024) |
Sign up to download Standigm's company profile
Standigm's funding and investors
Standigm has raised a total funding of $69.6M over 5 rounds. Its first funding round was on Feb 04, 2016. Its latest funding round was a Series C round on Jul 02, 2021 for $*****. 2 investors participated in its latest round. Standigm has 16 institutional investors.
Here is the list of recent funding rounds of Standigm:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 02, 2021 | 7759988 | Series C | 8788219 | 9417137 | 7308582 | 7270581 |
Mar 05, 2021 | 4240256 | Series C | 2910016 | 9412145 | 6645759 | |
Mar 28, 2019 | 2884859 | Series B | 3122488 | 9502398 |
Access funding benchmarks and valuations. Sign up today!View details of Standigm's funding rounds and investors
Standigm's founders and board of directors
Founder? Claim ProfileHere are the details of Standigm's key team members:
- Jinhan Kim: Co-Founder & CEO of Standigm. Contact Info: 1 email address
- So Jeong Yun: Co-Founder of Standigm. Contact Info: 1 email address
View details of Standigm's Founder profiles and Board Members
Standigm's employee count trend
Standigm has 25 employees as of Mar 26. Here is Standigm's employee count trend over the years:
Uncover Standigm's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Standigm's Competitors and alternates
Top competitors of Standigm include Recursion Pharmaceuticals, XtalPi and Schrodinger. Here is the list of Top 10 competitors of Standigm, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 72/100 | |
2nd |  XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
3rd |  Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 66/100 | |
4th |  Healx 2014, Cambridge (United Kingdom), Series C | AI-powered drug discovery platform to treat rare diseases | $115M | 64/100 | |
5th |  METiS Therapeutics 2017, Cambridge (United States), Series B | Provider of an AI-assisted platform for drug discovery and development | $252M | 63/100 | |
6th |  Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
7th |  Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 62/100 | |
8th | Provider of an AI and quantum physics to discover therapeutic molecules | $103M | 62/100 | ||
9th |  In Silico 2014, Cambridge (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 62/100 | |
10th |  Isomorphic Labs 2021, London (United Kingdom), Series D | AI-driven platform to accelerate drug discovery process | $600M | 62/100 | |
31st | Standigm 2015, Seoul (South Korea), Series C | AI-based platform for drug discovery and development | $69.6M | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Standigm's competitors? Click here to see the top ones
Standigm's Investments and acquisitions
Standigm has made no investments or acquisitions yet.
News related to Standigm
Filter this list•
Korea-US partnership to revolutionise AI-based early drug discoveryBioSpectrum Asia•Aug 17, 2023•Standigm, Nashville Biosciences
•
Standigm and Nashville Biosciences join to revolutionize early drug discoveryPR Newswire•Aug 10, 2023•Standigm, Nashville Biosciences
•
•
•
Standigm Synthetic Research Center successfully accelerates drug discovery in its first yearPR Newswire•Nov 17, 2022•Standigm
•
•
Standigm Wins Gold And Bronze Stevie® Awards In 2022 International Business Awards®PR Newswire•Aug 16, 2022•Standigm
•
Merck KGaA, South Korea's Standigm team up for AI-based drug discovery researchSeeking Alpha•Jun 01, 2022•Merck, Standigm
•
Standigm, Institut Pasteur Korea team up for AI-based drug discovery research on TBBioSpectrum Asia•Dec 03, 2021•Standigm, Ip Korea
•
Standigm Files PCT Patent Application for AI-driven Repurposed Drugs for Mitochondrial DiseaseBusinesskorea•Nov 04, 2021•Standigm
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Standigm
Explore our recently published companies
- Acemartech - 2020 founded, Unfunded company
- TreSkin - Grand Rapids based, 2007 founded, Unfunded company
- Mean and Green Microgreens - United States based, 2020 founded, Unfunded company
- Prashanti Sarees - Chennai based, 2016 founded, Unfunded company
- edXtra Tech - Nashik based, 2025 founded, Unfunded company
- CintaMedtech - 2019 founded, Unfunded company
